MX2011008917A - Peptidos vangl1 y vacunas que incluyen los mismos. - Google Patents
Peptidos vangl1 y vacunas que incluyen los mismos.Info
- Publication number
- MX2011008917A MX2011008917A MX2011008917A MX2011008917A MX2011008917A MX 2011008917 A MX2011008917 A MX 2011008917A MX 2011008917 A MX2011008917 A MX 2011008917A MX 2011008917 A MX2011008917 A MX 2011008917A MX 2011008917 A MX2011008917 A MX 2011008917A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- vangl1
- same
- vaccines including
- present
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 229960005486 vaccine Drugs 0.000 title 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000007792 addition Methods 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical class 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona péptidos aislados o los fragmentos derivados de la SEQ ID NO: 35, que enlazan a un antígeno HLA e inducen linfocitos T citotóxicos (CTL). Los péptídos pueden incluir una de las secuencias de aminoácido mencionadas arriba con sustitución, eliminación, o adición de uno, dos, o varias secuencias de aminoácido. La presente invención también proporciona composiciones farmacéuticas que incluyen estos péptidos. Los péptidos de esta invención pueden usarse para tratar cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20924209P | 2009-03-04 | 2009-03-04 | |
PCT/JP2010/001366 WO2010100878A1 (en) | 2009-03-04 | 2010-03-01 | Vangl1 peptides and vaccines including the same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011008917A true MX2011008917A (es) | 2011-09-09 |
Family
ID=42709447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011008917A MX2011008917A (es) | 2009-03-04 | 2010-03-01 | Peptidos vangl1 y vacunas que incluyen los mismos. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20120107333A1 (es) |
EP (1) | EP2403943A1 (es) |
JP (1) | JP2012519470A (es) |
KR (1) | KR20110134446A (es) |
CN (1) | CN102439147A (es) |
AU (1) | AU2010219951A1 (es) |
BR (1) | BRPI1012312A2 (es) |
CA (1) | CA2753681A1 (es) |
IL (1) | IL214453A0 (es) |
MX (1) | MX2011008917A (es) |
RU (1) | RU2011140168A (es) |
SG (1) | SG174206A1 (es) |
TW (1) | TW201043244A (es) |
WO (1) | WO2010100878A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201211250A (en) * | 2010-09-07 | 2012-03-16 | Oncotherapy Science Inc | VANGL1 peptides and vaccines including the same |
UA114298C2 (uk) | 2011-10-28 | 2017-05-25 | Онкотерапі Саєнс, Інк. | Пептид торк та вакцина, що його містить |
SG11201405578TA (en) | 2012-03-09 | 2014-11-27 | Oncotherapy Science Inc | Pharmaceutical composition containing peptide |
KR102492241B1 (ko) * | 2022-02-25 | 2023-01-30 | 전남대학교산학협력단 | Kitenin의 이량체 형성을 저해하는 펩타이드 및 이의 용도 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2399569A1 (en) * | 2001-09-25 | 2003-03-25 | Yusuke Nakamura | Diagnostic markers and drug targets for treatment of cancer |
EP1462456A4 (en) * | 2001-12-10 | 2005-09-21 | Greenpeptide Co Ltd | TUMOR ANTIGENS |
CN103073620B (zh) * | 2002-09-12 | 2014-12-10 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
DK2325306T3 (en) * | 2005-02-25 | 2014-03-03 | Oncotherapy Science Inc | Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide |
US8674059B2 (en) * | 2005-07-27 | 2014-03-18 | Oncotherapy Science, Inc. | Colon cancer related gene TOM34 |
CN102850435B (zh) * | 2006-10-17 | 2016-02-17 | 肿瘤疗法科学股份有限公司 | 用于表达mphosph1或depdc1多肽的癌症的肽疫苗 |
-
2010
- 2010-03-01 BR BRPI1012312A patent/BRPI1012312A2/pt not_active IP Right Cessation
- 2010-03-01 EP EP10748479A patent/EP2403943A1/en not_active Withdrawn
- 2010-03-01 WO PCT/JP2010/001366 patent/WO2010100878A1/en active Application Filing
- 2010-03-01 MX MX2011008917A patent/MX2011008917A/es not_active Application Discontinuation
- 2010-03-01 CN CN2010800196356A patent/CN102439147A/zh active Pending
- 2010-03-01 KR KR1020117023280A patent/KR20110134446A/ko not_active Application Discontinuation
- 2010-03-01 RU RU2011140168/10A patent/RU2011140168A/ru not_active Application Discontinuation
- 2010-03-01 US US13/203,939 patent/US20120107333A1/en not_active Abandoned
- 2010-03-01 JP JP2011537768A patent/JP2012519470A/ja active Pending
- 2010-03-01 CA CA2753681A patent/CA2753681A1/en not_active Abandoned
- 2010-03-01 AU AU2010219951A patent/AU2010219951A1/en not_active Abandoned
- 2010-03-01 SG SG2011063120A patent/SG174206A1/en unknown
- 2010-03-02 TW TW099105932A patent/TW201043244A/zh unknown
-
2011
- 2011-08-04 IL IL214453A patent/IL214453A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2011140168A (ru) | 2013-04-10 |
KR20110134446A (ko) | 2011-12-14 |
EP2403943A1 (en) | 2012-01-11 |
TW201043244A (en) | 2010-12-16 |
BRPI1012312A2 (pt) | 2017-03-21 |
WO2010100878A1 (en) | 2010-09-10 |
CN102439147A (zh) | 2012-05-02 |
SG174206A1 (en) | 2011-10-28 |
JP2012519470A (ja) | 2012-08-30 |
IL214453A0 (en) | 2011-09-27 |
US20120107333A1 (en) | 2012-05-03 |
AU2010219951A1 (en) | 2011-08-25 |
CA2753681A1 (en) | 2010-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
MX2011008763A (es) | Peptidos foxm1 y vacunas que contienen los mismos. | |
UA103751C2 (ru) | Иммуногенный пептид для иммунотерапии | |
EP3412304A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
WO2009025196A1 (ja) | Foxm1ペプチドおよびこれを含む薬剤 | |
MX2009010965A (es) | Péptidos de tem8 y vacunas que los contienen. | |
SG10201407944TA (en) | Imp-3 oligopeptides and vaccines including the same | |
MX355759B (es) | Peptidos topk y vacunas que incluyen los mismos. | |
MX2009007261A (es) | Vacuna de peptido foxp3. | |
MX2013014489A (es) | Peptidos sema5b y vacunas que incluyen los mismos. | |
MX2012011668A (es) | Peptidos cdca5 y vacunas que incluyen los mismos. | |
EP2528937A4 (en) | MODIFIED MELK PEPTIDES AND ASSOCIATED VACCINES | |
MY166516A (en) | Tomm34 peptides and vaccines including the same | |
MX2011008917A (es) | Peptidos vangl1 y vacunas que incluyen los mismos. | |
EP3556857A3 (en) | Cdc45l peptides and vaccines including the same | |
UA102274C2 (ru) | Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат | |
MX2012006770A (es) | Peptidos tmem22 y vacunas que incluyen los mismos. | |
MX2013004417A (es) | Peptidos wdhd1 y vacunas que los incluyen. | |
MX2012011385A (es) | Peptidos ect2 y vacunas que los incluyen. | |
BR112013009276A2 (pt) | peptídeos de c18orf54 e vacinas incluindo os mesmos | |
EP2370454A4 (en) | PEPTIDES WITH EPITAOPE WDRPUH AND VACCINES INCLUDING THEM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |